Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Mudde

G. C. Mudde, Breitenfurt AT

Patent application number	Description	Published
20090104268	Nanoparticles Comprising Antigens and Adjuvants, and Immunogenic Structures - Nanoparticles comprising adjuvants and antigens, such as tumour and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.	04-23-2009

Geert Mudde, Breitenfurt AT

Patent application number	Description	Published
20100184615	Display of Binding Agents - The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.	07-22-2010
20110046355	CYTOTOXIC IMMUNOGLOBULIN - The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd<10	02-24-2011

Geert Mudde, Wien AT

Patent application number	Description	Published
20100143342	BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES - A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, its production and its use a medicament, especially for the treatment of allergies.	06-10-2010

Geert C. Mudde, Breitenfurt AT

Patent application number	Description	Published
20090220521	Anti MIF Antibodies - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.	09-03-2009
20100260768	ANTI MIF ANTIBODIES - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.	10-14-2010
20110020331	N-GLYCOSYLATED ANTIBODY - The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.	01-27-2011